www.fdanews.com/articles/203163-jj-abbvie-release-positive-phase-3-results-for-imbruvica-combo
J&J, AbbVie Release Positive Phase 3 Results for Imbruvica Combo
June 15, 2021
Johnson & Johnson (J&J) and AbbVie have announced that their BTK inhibitor Imbruvica (ibrutinib) plus Venclexta (venetoclax) helped elderly cancer patients live longer without disease progression in a late-stage trial compared with chemoimmunotherapy.
The phase 3 study evaluated the Imbruvica combination vs. chlorambucil plus obinutuzumab as a first-line treatment in 211 participants with either chronic lymphocytic leukemia or small lymphocytic lymphoma.
The data provide “the first comparative evidence” that the Imbruvica combination has the potential to extend time to disease progression vs. standard therapy,” said Arnon Kater, the trial’s lead investigator.